Advanced search
1 file | 1.13 MB Add to list

Metabolic modulation during intestinal fibrosis

Simon Bos (UGent) and Debby Laukens (UGent)
(2020) JOURNAL OF DIGESTIVE DISEASES. 21(6). p.319-325
Author
Organization
Abstract
Intestinal fibrosis is one of the biggest challenges in the therapeutic management of inflammatory bowel diseases (IBD). Patients with Crohn's disease, in particular, suffer from fibrotic complications, which are manifested by the clinical stenosis of the bowel. Although fibrosis is caused by recurrent episodes of inflammation and wound healing, current therapies for IBD do not seem to reduce the incidence of stenosis, suggesting that inflammation-independent mechanisms also contribute to intestinal fibrogenesis. The lack of anti-fibrotic therapies for IBD and the huge burden this complication places on patients has prompted us to redirect inflammation research toward understanding the mechanisms that drive gut fibrosis. Based on data from other fibroproliferative diseases, metabolic modifications are increasingly recognized as pathogenic processes that may generate new therapeutic opportunities. These metabolic alterations result from a switch in the cellular metabolism of activated fibroblasts, which are the key mediator cells of fibrosis. Here, we review the metabolic changes associated with fibrotic disease and summarize the evidence of a metabolic shift during intestinal fibrosis.
Keywords
Gastroenterology, fatty acid metabolism, fibroblasts, glutaminolysis, glycolysis, intestinal fibrosis, metabolic reprogramming, CONNECTIVE-TISSUE CHANGES, AEROBIC GLYCOLYSIS, FATTY-ACID, MYOFIBROBLAST DIFFERENTIATION, CROHNS-DISEASE, GLUTAMINE, HYPOXIA, GROWTH, EXPRESSION, AUTOPHAGY

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.13 MB

Citation

Please use this url to cite or link to this publication:

MLA
Bos, Simon, and Debby Laukens. “Metabolic Modulation during Intestinal Fibrosis.” JOURNAL OF DIGESTIVE DISEASES, vol. 21, no. 6, 2020, pp. 319–25, doi:10.1111/1751-2980.12882.
APA
Bos, S., & Laukens, D. (2020). Metabolic modulation during intestinal fibrosis. JOURNAL OF DIGESTIVE DISEASES, 21(6), 319–325. https://doi.org/10.1111/1751-2980.12882
Chicago author-date
Bos, Simon, and Debby Laukens. 2020. “Metabolic Modulation during Intestinal Fibrosis.” JOURNAL OF DIGESTIVE DISEASES 21 (6): 319–25. https://doi.org/10.1111/1751-2980.12882.
Chicago author-date (all authors)
Bos, Simon, and Debby Laukens. 2020. “Metabolic Modulation during Intestinal Fibrosis.” JOURNAL OF DIGESTIVE DISEASES 21 (6): 319–325. doi:10.1111/1751-2980.12882.
Vancouver
1.
Bos S, Laukens D. Metabolic modulation during intestinal fibrosis. JOURNAL OF DIGESTIVE DISEASES. 2020;21(6):319–25.
IEEE
[1]
S. Bos and D. Laukens, “Metabolic modulation during intestinal fibrosis,” JOURNAL OF DIGESTIVE DISEASES, vol. 21, no. 6, pp. 319–325, 2020.
@article{8665368,
  abstract     = {Intestinal fibrosis is one of the biggest challenges in the therapeutic management of inflammatory bowel diseases (IBD). Patients with Crohn's disease, in particular, suffer from fibrotic complications, which are manifested by the clinical stenosis of the bowel. Although fibrosis is caused by recurrent episodes of inflammation and wound healing, current therapies for IBD do not seem to reduce the incidence of stenosis, suggesting that inflammation-independent mechanisms also contribute to intestinal fibrogenesis. The lack of anti-fibrotic therapies for IBD and the huge burden this complication places on patients has prompted us to redirect inflammation research toward understanding the mechanisms that drive gut fibrosis. Based on data from other fibroproliferative diseases, metabolic modifications are increasingly recognized as pathogenic processes that may generate new therapeutic opportunities. These metabolic alterations result from a switch in the cellular metabolism of activated fibroblasts, which are the key mediator cells of fibrosis. Here, we review the metabolic changes associated with fibrotic disease and summarize the evidence of a metabolic shift during intestinal fibrosis.},
  author       = {Bos, Simon and Laukens, Debby},
  issn         = {1751-2972},
  journal      = {JOURNAL OF DIGESTIVE DISEASES},
  keywords     = {Gastroenterology,fatty acid metabolism,fibroblasts,glutaminolysis,glycolysis,intestinal fibrosis,metabolic reprogramming,CONNECTIVE-TISSUE CHANGES,AEROBIC GLYCOLYSIS,FATTY-ACID,MYOFIBROBLAST DIFFERENTIATION,CROHNS-DISEASE,GLUTAMINE,HYPOXIA,GROWTH,EXPRESSION,AUTOPHAGY},
  language     = {eng},
  number       = {6},
  pages        = {319--325},
  title        = {Metabolic modulation during intestinal fibrosis},
  url          = {http://dx.doi.org/10.1111/1751-2980.12882},
  volume       = {21},
  year         = {2020},
}

Altmetric
View in Altmetric
Web of Science
Times cited: